| 1 |
33216879 | Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. | 2021 May 22 |
1 |
| 2 |
33813847 | Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. | 2021 Jun |
1 |
| 3 |
33954871 | Cardiac medication use in patients with suspected ischaemia without obstructive coronary arteries: sex differences and psychological distress. | 2021 Oct |
1 |
| 4 |
34001757 | Sex differences in the antihypertensive treatment and risk of uncontrolled hypertension in 5308 hypertensive patients in the United Arab Emirates. | 2021 Oct 1 |
1 |
| 5 |
30821177 | Pre-fracture medication use as a predictor of 30-day mortality in hip fracture patients: an analysis of 141,201 patients. | 2020 Jan |
1 |
| 6 |
32395481 | TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension. | 2020 Apr |
2 |
| 7 |
32550191 | Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients. | 2020 Jun |
1 |
| 8 |
32931573 | Autonomic Dysfunction and Blood Pressure in Glaucoma Patients: The Lifelines Cohort Study. | 2020 Sep 1 |
2 |
| 9 |
33349633 | Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. | 2020 Dec 22 |
1 |
| 10 |
31965780 | ACE-inhibitor/calcium antagonist combination: is this the first-choice therapy in arterial hypertension? | 2019 Dec |
1 |
| 11 |
25485720 | Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. | 2015 Feb |
1 |
| 12 |
26197790 | Association of calcium antagonist use with lower hemoglobin levels in hemodialysis patients. | 2015 Sep |
1 |
| 13 |
25102744 | [Results of the Russian EKSPERT program: post-marketing supervision over efficacy and influence of the preparation Ekvator on quality of life at out-patients with arterial hypertension]. | 2014 |
1 |
| 14 |
17011715 | Calcific aortic valve disease should not be considered as a degenerative disease anymore. | 2007 |
1 |
| 15 |
17204161 | Dietary calcium intake and renin angiotensin system polymorphisms alter the blood pressure response to aerobic exercise: a randomized control design. | 2007 Jan 4 |
1 |
| 16 |
17474500 | [Diabetes prevention in hypertensive patients]. | 2007 Feb |
1 |
| 17 |
16518351 | ACE-inhibitor use and the long-term risk of renal failure in diabetes. | 2006 Mar |
1 |
| 18 |
16373953 | The role of dairy foods in weight management. | 2005 Dec |
2 |
| 19 |
28102744 | Stroke Prevention: Not all Antihypertensive Drugs are Created Equal. | 2005 Mar |
1 |
| 20 |
15032651 | The possible therapeutic actions of peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, PPAR gamma agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium (Ca)-antagonists on vascular endothelial cells. | 2004 Mar |
1 |
| 21 |
15488653 | Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension. | 2004 |
2 |
| 22 |
15526242 | The role of the renin-angiotensin-aldosterone system in heart failure. | 2004 Sep |
1 |
| 23 |
12610747 | Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors. | 2003 Feb |
5 |
| 24 |
12775305 | Clinical efficacies of antihypertensive drugs. | 2003 May |
2 |
| 25 |
12799093 | Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. | 2003 Jun |
1 |
| 26 |
11815428 | Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. | 2002 Jan 29 |
1 |
| 27 |
11999543 | Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. | 2002 Apr |
1 |
| 28 |
12222627 | Evolving therapeutic strategies for retarding progression of diabetic nephropathy--an update for 2002. | 2002 Jun |
1 |
| 29 |
12420192 | Are we negating the benefits of CABG by forgetting secondary prevention? | 2002 Oct |
1 |
| 30 |
12489793 | Activation of bradykinin B1 receptor by ACE inhibitors. | 2002 Dec |
1 |
| 31 |
12652116 | Beta-blockers and diabetes: the bad guys come good. | 2002 Sep |
1 |
| 32 |
10757223 | Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes? | 2000 Mar |
1 |
| 33 |
11090788 | Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. | 2000 Dec 1 |
1 |
| 34 |
10077416 | Renoprotective effects of antihypertensive drugs. | 1999 Jan |
1 |
| 35 |
9674632 | Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. | 1998 Jul |
1 |
| 36 |
9736438 | Evidence-based medicine and ACE inhibition. | 1998 |
1 |
| 37 |
9799051 | The rationale for combination versus single-entity therapy in hypertension. | 1998 Oct |
5 |
| 38 |
9822144 | Calcium antagonists and the diabetic patient: a response to recent controversies. | 1998 Nov 12 |
3 |
| 39 |
9855029 | Existing treatment strategies: does noncompliance make a difference? | 1998 Sep |
1 |
| 40 |
9869001 | Vascular protection with newer antihypertensive agents. | 1998 Oct |
2 |
| 41 |
10099077 | University of Miami Division of Clinical Pharmacology Therapeutic Rounds: managing hypertension in patients with kidney disease-implications for preservation of renal function. | 1998 Sep |
1 |
| 42 |
18370550 | Amlodipine in ischaemic left ventricular dysfunction with mild to moderate heart failure. | 1998 |
1 |
| 43 |
9037321 | The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance. | 1997 Feb |
2 |
| 44 |
9218196 | Complementary actions and risk reduction: the rationale for combination of an angiotensin converting enzyme inhibitor with a non-dihydropyridine calcium antagonist. | 1997 Mar |
1 |
| 45 |
9231892 | Combination treatment in hypertension: the VeraTran Study. | 1997 Jul |
2 |
| 46 |
9231894 | The challenge of managing multiple cardiovascular risk factors. | 1997 Jul |
1 |
| 47 |
9324122 | Combination therapy and target organ protection in hypertension and diabetes mellitus. | 1997 Sep |
1 |
| 48 |
9493699 | Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. | 1997 Nov |
1 |
| 49 |
8602055 | Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. | 1996 Apr 20 |
1 |
| 50 |
8769047 | Trends in the use of blood pressure lowering medications in Auckland, and associated costs, 1982-94. | 1996 Jul 26 |
1 |